Association between metabolic syndrome and colorectal carcinoma based on a casecontrol study

doi:10.3760/cma.j.issn.1673-422X.2018.09.006

Abstract

Abstract: ObjectiveTo evaluate the association between metabolic syndrome and colorectal carcinoma. MethodsA total of 900 patients with colorectal carcinoma from 2013 to 2016 in Qianfoshan Hospital Affiliated to Shandong University were selected as the case group and 1 774 noncolorectal carcinoma participants from health management center as the control group. Logistic regression model was used to identify the relationship between metabolic syndrome and colorectal carcinoma. ResultsCompared with the controls (27.0%), metabolic syndrome was more prevalent among cases (35.4%). The difference was statistically significant (χ2=20.33, P<0.01). Multivariate logistic regression analyses showed that metabolic syndrome as an entity increased colorectal carcinoma risk (OR=1.38, 95%CI: 1.081.75, χ2=17.68, P＜0.01). Subjects with 2 and 3 or more components of the metabolic syndrome had an increased risk of colorectal carcinoma, and the ORs of colorectal carcinoma were 1.37 and 1.60, respectively. Genderspecific patterns were also observed in the association between metabolic syndrome, component and colorectal carcinoma (χ2=5.40, P=0.02; χ2=8.66, P<0.01). ConclusionMetabolic syndrome is associated with the occurrence of colorectal carcinoma. An increasing trend in risk of colorectal carcinoma with the number of metabolic syndrome components is observed.

Key words: Metabolic syndrome X, Colorectal neoplasms, Casecontrol studies

Lian Ying, Wang Linping, Liang Jing, Tang Fang. Association between metabolic syndrome and colorectal carcinoma based on a casecontrol study[J]. Journal of International Oncology, 2018, 45(8): 539-543.

References

［1］孙惠昕, 陈王洋, 张茂祥, 等. 2013年黑龙江省肿瘤登记地区恶性肿瘤发病与死亡分析［J］. 国际肿瘤学杂志, 2017, 44(11): 828833. DOI: 10.3760/cma.j.issn.1673422X.2017.11.006. ［2］ Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014［J］. CA Cancer J Clin, 2014, 64(2): 104117. DOI: 10.3322/caac.21220. ［3］李明伶, 冯斐, 燕锦, 等. 腌腊肉制品摄入及与其他饮食习惯、生活方式的交互作用和结直肠癌发生风险的探讨［J］. 中华流行病学杂志, 2016, 37(7): 10061011. DOI: 10.3760/cma.j.issn.02546450.2016.07.020. ［4］ Akinyemiju T, Do AN, Patki A, et al. Epigenomewide association study of metabolic syndrome in AfricanAmerican adults［J］. Clin Epigenetics, 2018, 10: 49. DOI: 10.1186/s1314801804832. ［5］罗燕, 陶丽新, 张莹, 等. γ谷氨酰转肽酶水平与代谢综合征及其组分间关系［J］. 中国公共卫生, 2017, 33(8): 11891192. DOI: 10.11847/zgggws2017330808. ［6］ Ahmed RL, Schmitz KH, Anderson KE, et al. The metabolic syndrome and risk of incident colorectal cancer［J］. Cancer, 2006, 107(1): 2836. DOI: 10.1002/cncr.21950. ［7］李莉, 黄河浪, 张熙赘, 等. 代谢综合征与结直肠癌的相关性研究［J］. 中华胃肠外科杂志, 2011, 14(12): 948951. DOI: 10.3760/cma.j.issn.16710274.2011.12.010. ［8］中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议［J］. 中华糖尿病杂志, 2004, 12(3): 156161. DOI: 10.3321/j.issn:10066187.2004.03.002. ［9］张惠博, 杨琰, 宋启斌. MTHFR基因多态性与结直肠癌的相关性［J］. 国际肿瘤学杂志, 2017, 44(8): 619621. DOI: 10.3760/cma.j.issn.1673422X.2017.08.016. ［10］ Liu JJ, Druta M, Shibata D, et al. Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptormediated angiogenesis a critical process?［J］. J Geriatr Oncol, 2014, 5(1): 4048. DOI: 10.1016/j.jgo.2013.11.004. ［11］ Kabat GC, Kim MY, Stefanick M, et al. Metabolic obesity phenotypes and risk of colorectal cancer in postmenopausal women［J］. Int J Cancer, 2018, 143(3): 543551. DOI: 10.1002/ijc.31345. ［12］吴小利, 高昕, 刘晗, 等. IGFI与IGFBP3在结直肠癌患者血清中表达的临床意义［J］. 中华检验医学杂志, 2017, 40(11): 871875. DOI: 10.3760/cma.j.issn.10099158.2017.11.009. ［13］ Kim IH, Nam TJ. Fucoidan downregulates insulinlike growth factorⅠ receptor levels in HT29 human colon cancer cells［J］. Oncol Rep, 2018, 39(3): 15161522. DOI: 10.3892/or.2018.6193. ［14］ Lu Y, NessJensen E, Hveem K, et al. Metabolic predispositions and increased risk of colorectal adenocarcinoma by anatomical location: a large populationbased cohort study in Norway［J］. Am J Epidemiol, 2015, 182(10): 883893. DOI: 10.1093/aje/kwv141. ［15］ Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk［J］. Eur J Cancer, 2008, 44(2): 293297. DOI: 10.1016/j.ejca.2007.11.005. ［16］ Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study［J］. Cancer Prev Res, 2011, 4(11): 18731883. DOI: 10.1158/19406207.CAPR110218.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[8]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[10]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[11]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[12]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[13]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.
[14]	Zhao Ying, Zhang Gehong. Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer [J]. Journal of International Oncology, 2022, 49(8): 473-477.
[15]	Huang Mengpan, Wang Xuehong, Lu Yongfu. Mechanism of FOXA2 in colorectal cancer and its application in diagnosis and treatment [J]. Journal of International Oncology, 2022, 49(8): 490-493.